You have 9 free searches left this month | to do more

sitravatinib

Sitravatinib is a drug used to treat Carcinoma, Non-Small-Cell Lung, Clear Cell Renal Cell Carcinoma, Healthy Adults, and other conditions. Sitravatinib is being actively studied in 21 studies and prior, has been studied in 3.

Top SponsorsTop SitesTop Investigators
Mirati Therapeutics Inc.Beijing Cancer HospitalDo-Youn Oh
BeiGeneBeverly Hills Cancer CenterJun Guo
Fudan UniversityTexas Oncology - TylerMaryam Nemati Shafaee
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
B
Completed
  • Tumor
  • Sitravatinib
  • Nedlands, Western Australia, Australia
    Linear Clinical Research Pty Lt(LCR)
2021-11-05
Nov 5, 2021
M
Completed
  • Healthy Adults
  • sitravatinib
  • Dallas, Texas
    Covance Clinical Research Unit, Inc.
2022-04-04
Apr 4, 2022
S
Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +8 more
  • New Haven, Connecticut
    Yale University
2022-02-17
Feb 17, 2022
B
Recruiting
  • Melanoma
  • Beijing, Beijing, China
    Beijing Cancer Hospital
2021-11-02
Nov 2, 2021
F
Recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
2021-12-15
Dec 15, 2021
Z
Not yet recruiting
  • Lung Cancer, Small Cell
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
2022-02-07
Feb 7, 2022
M
Recruiting
  • Breast Cancer Stage IV
  • +3 more
  • Sitravatinib
  • Houston, Texas
    Baylor College of Medicine
2021-06-01
Jun 1, 2021
M
Recruiting
  • Hepatic Impairment
  • sitravatinib
  • Tustin, California
  • +4 more
2022-04-04
Apr 4, 2022
B
M
Recruiting
  • Advanced Solid Tumor
  • Sitravatinib
  • +6 more
  • Goshen, Indiana
  • +3 more
2022-02-02
Feb 2, 2022
M
Active, not recruiting
  • Clear Cell Renal Cell Carcinoma
  • Houston, Texas
    MD Anderson Cancer Center
2021-04-27
Apr 27, 2021
M
Active, not recruiting
  • Healthy Adults
  • Sitravatinib
  • +2 more
  • Madison, Wisconsin
    Covance Clinical Research Unit Inc.
2021-11-24
Nov 24, 2021
M
Not yet recruiting
  • Advanced Clear Cell Renal Cell Carcinoma
  • +2 more
  • Nivolumab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-06-10
Jun 10, 2021
U
Completed
  • Squamous Cell Carcinoma, Head And Neck
  • +2 more
  • Sitravatinib
  • Nivolumab
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-03-30
Mar 30, 2021
M
Recruiting
  • Advanced or Metastatic Solid Malignancies
  • Sitravatinib
  • +4 more
  • Beverly Hills, California
  • +5 more
2021-11-04
Nov 4, 2021
M
Enrolling by invitation
  • Clear-Cell Renal Cell Carcinoma
  • Sitravatinib
  • +2 more
  • Houston, Texas
    MD Anderson
2022-01-23
Jan 23, 2022
M
Active, not recruiting
  • Clear Cell Renal Cell Carcinoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-25
Feb 25, 2022
S
Recruiting
  • Advanced Biliary Tract Cancer
  • Seoul, Korea, Republic of
    Seoul National University Hospital
2021-01-23
Jan 23, 2021
B
Active, not recruiting
  • Advanced Solid Tumors
  • Sitravatinib
  • Blacktown, New South Wales, Australia
  • +16 more
2022-02-04
Feb 4, 2022
M
Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Yuma, Arizona
  • +23 more
2021-08-17
Aug 17, 2021
M
Recruiting
  • Urothelial Carcinoma
  • +4 more
  • Sitravatinib
  • +3 more
  • Tucson, Arizona
  • +33 more
2021-05-21
May 21, 2021
U
Active, not recruiting
  • Non-Small Cell Lung Cancer
  • +2 more
  • Aberdeen, United Kingdom
  • +24 more
2021-11-02
Nov 2, 2021
M
Recruiting
  • Metastatic Non-Squamous Non-Small Cell Lung Cancer
  • Nivolumab
  • +2 more
  • Birmingham, Alabama
  • +235 more
2022-03-25
Mar 25, 2022